Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01589289
Other study ID # WP2-01-NEU
Secondary ID
Status Completed
Phase Phase 3
First received April 26, 2012
Last updated January 15, 2016
Start date September 2012
Est. completion date May 2015

Study information

Verified date January 2016
Source Institute of Tropical Medicine, Belgium
Contact n/a
Is FDA regulated No
Health authority Congo, Democratic Republic of the: Ministry of Health
Study type Interventional

Clinical Trial Summary

The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management. In sub-Saharan Africa, the few observational studies conducted for the past 20 years show that neurological disorders accounted for 7 to 24% of all admissions. Central nervous system (CNS) infections were suspected in one third of all patients admitted with neurological symptoms, with a specific microbial aetiology identified in half of these. Most CNS infections may be considered as "severe and treatable diseases", e.g. human African trypanosomiasis (HAT), cerebral malaria, bacterial meningitis, CNS tuberculosis etc. If left untreated, death or serious sequels occur (mortality rates were as high as 30% in the above mentioned studies), but the outcome may be favourable with timely and appropriate management.

In poor settings, such conditions should be targeted in priority in the clinical decision-making process. Unfortunately, most neuro-infections present with non-specific symptoms in their early stages, leading to important diagnostic delays. Moreover, they require advanced diagnostic technology, which is not available in most tropical rural settings: here, you have to rely on clinical judgment and first-line laboratory results, whose confirming or excluding powers are limited or unknown. Several rapid diagnostic tests (RDTs) have been recently developed for conditions like malaria or HIV, but their diagnostic contribution has not been evaluated within a multi-disease approach.

Thus, this research aims at improving the early diagnosis of severe and treatable neglected and non-neglected infectious diseases which present with neurological symptoms in the province of Bandundu, Democratic Republic of Congo (DRC), by combining classic clinical predictors with a panel of simple point-of-care rapid diagnostic tests.

The evaluation of existing algorithms and elaboration/validation of new guidelines will be described in a subsequent protocol.


Description:

The impact of neurological disorders is enormous in terms of mortality, morbidity, physical disability and psychological distress, and it is increased in low-resource settings by lack of diagnosis and of treatment facilities as well as delayed management. The frequency of neurological disorders and the pattern of causative conditions are little documented in low-resource primary care settings.In sub-Saharan Africa, the few observational studies conducted for the past 20 years, show that neurological disorders accounted for 7 to 24% of all admissions. Central nervous system (CNS) infections were suspected in one third of all patients admitted with neurological symptoms, with a specific microbial aetiology identified in half of these. Where it has been investigated, up to one third of neurological admissions was related to HIV infection in some settings. Neuro-infections were also the leading aetiologies of common neurological symptoms (such as headache) in African HIV-positive patients, and autopsy studies have demonstrated that CNS infections accounted for 20% of the causes of death in HIV-positive individuals in sub-Saharan Africa.

Most CNS infections may be considered as "severe and treatable diseases", e.g. human African trypanosomiasis (HAT), cerebral malaria, bacterial meningitis, CNS tuberculosis, neurosyphilis, cryptococcal meningitis or toxoplasma encephalitis etc. If left untreated, death or serious sequels usually occur; mortality rates of neurological admissions were as high as 30% in the above mentioned studies. However, outcome may be favourable with timely and appropriate management.

In resource-constrained settings more than elsewhere, such "severe and treatable" conditions should be targeted in priority in the clinical decision-making process. Unfortunately, most neuro-infections present with non-specific symptoms in their early stages, leading to important diagnostic delays. Moreover, neurological diagnoses frequently require advanced technology, but this is far beyond reach of most tropical rural settings, where you have to rely on clinical judgment and first-line laboratory results. However, the confirming or excluding powers of most clinical and laboratory features are limited or have never been adequately quantified, in particular in settings lacking reference diagnostic methods. Several rapid diagnostic tests (RDTs) have been developed in the last decade for conditions like malaria or HIV infection, but their diagnostic contribution has never been evaluated within a multi-disease approach. Most CNS infections with worldwide distribution affect disproportionally the (sub)-tropical regions, while others are restricted to the tropics. Also, many infections with potential neuropathogenicity belong to the group of 17 Neglected Tropical Diseases (NTDs) on which attention has been recently brought. As said above, most of them may be considered as "severe and treatable"; however, in most tropical settings, epidemiology of NTDs and other infectious diseases (IDs) is largely unknown, seriously impairing the case finding and clinical decision-making.

The aim of this research therefore is to improve the early diagnosis of severe and treatable neglected and non-neglected infectious diseases which may present with neurological symptoms in the province of Bandundu, Democratic Republic of Congo (DRC). This will be achieved through the elaboration and validation of new diagnostic guidelines based on epidemiological evidence, combining classic clinical predictors with a panel of simple point-of-care rapid diagnostic tests, and designed with a "panoramic" (not-to-miss) approach.

In particular, the investigators hope to determine the pre-test probability of HAT and other priority neglected tropical diseases/infectious diseases in patients presenting with neurological disorders; to assess the predictive weight of clinical and first-line laboratory features in the diagnosis of HAT and other priority NTDs/IDs; to assess the sensitivity, specificity and predictive values of novel point-of-care RDTs for the diagnosis of HAT and other priority NTDs/IDs in patients with neurological disorders; and to assess the diagnostic performances of combinations of novel and existing RDTs for diagnosing HAT and other priority NTDs/IDs in patients with neurological disorders. Enrolled patients will be managed according the current standard of care in Bandundu, DRC and with the treatments locally available through health facilities/programs.

The objectives and methodology of this second step of our research (evaluation of existing algorithms and elaboration/validation of new guidelines) will be described in a subsequent protocol. Another similar study (described in another protocol) will be conducted in parallel to explore the aetiologies of prolonged fever in the same setting.


Recruitment information / eligibility

Status Completed
Enrollment 352
Est. completion date May 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 5 Years and older
Eligibility Inclusion Criteria:

- Patients > 5 years-old AND

- Altered state of consciousness (confusion to coma) OR/AND

- Changes of sleep pattern (daytime slumber, night insomnia)OR/AND

- Cognitive decline OR/AND

- Changes in personality/behaviour (e.g. bouts of mania)OR/AND

- Epileptic seizure(s)OR/AND

- Daily severe/progressive headache OR/AND

- Meningismus (headache, neck stiffness, nausea/vomiting, photophobia)

- Cranial nerve lesions OR/AND

- Sensory-motor deficits or other focal neurological signs (e.g. dysphagia, dysarthria, ataxia, dystonia,...)OR/AND

- Gait disorders (e.g. spastic or ataxic gait)

Exclusion Criteria:

- Those unwilling or unable to give written informed consent (either directly or via proxy)

- Those unable in the physician's opinion to comply with the study requirements

- Neurological symptom unequivocally related with recent trauma

- Neurological symptom as sequelae of previous well-established neurological events (e.g. stroke,…)

- First seizure below 6 years of age (early onset seizure)

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Device:
Immunochromatographic HAT tests (DSD)
Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
Card Agglutination Trypanosoma Test
Card Agglutination Trypanosoma Test on whole blood and as dilution
TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
TB POC Nucleic Acid Amplification Test: "microPCR handheld device" (Molbio Diagnostics PVT ltd, India)
TB 3-marker RDT (Tulip diagnostics)
TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
Cryptococcal Antigen Lateral Flow Assay (Immy)
Cryptococcal Antigen Lateral Flow Assay (Immy, USA)

Locations

Country Name City State
Congo, The Democratic Republic o Reference Hospital Mosango Mosango Bandundu

Sponsors (3)

Lead Sponsor Collaborator
Institute of Tropical Medicine, Belgium Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, University Hospital, Geneva

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of HAT and other NTDs/IDs Number of patients diagnosed with HAT and other NTDs/IDs among those presenting with neurological disorders in rural hospitals of Bandundu, DRC (pre-test probability) 18 months No
Primary Identification of reliable diagnostic tests Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) of the novel study RDTs for the respective target conditions, and identification of those that should be included in future diagnostic protocols 18 months No
Primary Predictive values of RDTs Predictive values (post-test probabilities) of novel and existing RDTs, alone and in combination, for the respective target conditions within this multi-disease approach 18 months No
Primary Identification of clinical and laboratory diagnostic indicators Assessment of the specificity of the different clinical and first-line laboratory features for the diagnosis of HAT and other priority NTDs/IDs in the setting, for determining those that should be included in future diagnostic protocols 18 months No
Secondary Cure rate Number of patients who positively respond to specific/empirical therapies, as assessed as final patient outcomes (cure, referral, sequelae, death) 18 months Yes
Secondary Cost-effectiveness of the diagnostic tests Unit costs of diagnostic tests for the diagnosis of HAT and other priority NTDs/IDs in the setting 18 months No
See also
  Status Clinical Trial Phase
Completed NCT00976040 - Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis Phase 4
Completed NCT04031833 - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) Phase 1/Phase 2
Completed NCT00830856 - Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa N/A
Completed NCT04532463 - Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis
Completed NCT02098525 - Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy N/A
Completed NCT01075152 - Cryptococcal Optimal ART Timing Trial Phase 4
Active, not recruiting NCT01715922 - Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Phase 2/Phase 3
Completed NCT00145249 - Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis Phase 2
Completed NCT01802385 - Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Phase 3
Terminated NCT00324025 - Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Phase 2
Completed NCT02955862 - Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report Phase 1
Recruiting NCT03945448 - Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia Phase 2/Phase 3
Active, not recruiting NCT02624453 - Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS N/A
Recruiting NCT00867269 - Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Completed NCT01535469 - Operational Research for Cryptococcal Antigen Screening Phase 4
Active, not recruiting NCT04072640 - Three Induction Treatments on Cryptococcal Meningitis Early Phase 1
Not yet recruiting NCT05541107 - Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3 Phase 3
Not yet recruiting NCT02686853 - Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Phase 4
Not yet recruiting NCT04140461 - AmB Dose for Cryptococcal Meningitis Phase 3
Completed NCT04296292 - The Lived Experience of Participants in an African Randomised Trial